- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT00405418
Lantus Versus Levemir Treat-To-Target (L2T3)
Target Glycemic Control and the Incidence of Documented Symptomatic Hypoglycemia in Insulin naïve Subjects With Type 2 Diabetes Failing on Oral Hypoglycemic Agent(s) and Treated With Insulin Glargine or Insulin Detemir.
Primary objective:
To demonstrate the non-inferiority of insulin glargine in comparison to insulin detemir in term of percentage of patients who reach the target of HbA1c < 7% at the end of the treatment period and do not experience symptomatic hypoglycemia, confirmed by plasma glucose (PG) ≤ 56 mg/dL (3.1 mmol/L)
Secondary objectives:
- To compare between the 2 treatment groups, the percentage of patients who reach the target of HbA1c < 7% and < 6.5% at the end of the treatment period
- To compare the changes in HbA1c and fasting plasma glucose (FPG)
- To compare the evolution of blood glucose profiles
- To compare the day to day FPG variability, the insulin doses
- To determine in each treatment group the biochemical and patient-related determinants of failure to reach HbA1c targets
- To compare the overall incidence and rate of symptomatic hypoglycemia and nocturnal symptomatic hypoglycemia confirmed by PG ≤ 56 mg/dL (3.1 mmol/L)
- To compare over the treatment period, the overall incidence and rate of symptomatic hypoglycemia and symptomatic nocturnal hypoglycemia (with PG ≤ 70 mg/dL [3.9 mmol/L]), of symptomatic day-time hypoglycemia (with PG ≤ 70 mg/dL and with PG ≤ 56 mg/dL), of severe hypoglycemia, of asymptomatic hypoglycemia with PG ≤ 56 mg/dL
- To compare the overall safety: incidence of adverse events (including serious hypoglycemia and local tolerance at injection site), change in body weight, in waist circumference and in waist / hip ratio
- To assess the quality of life and treatment satisfaction
Studie Overzicht
Toestand
Conditie
Interventie / Behandeling
Studietype
Inschrijving (Werkelijk)
Fase
- Fase 4
Contacten en locaties
Studie Locaties
-
-
-
North Ryde, Australië
- Sanofi-Aventis
-
-
-
-
-
Sao Paolo, Brazilië
- Sanofi-Aventis
-
-
-
-
-
Laval, Canada
- Sanofi-Aventis
-
-
-
-
-
Hoersholm, Denemarken
- Sanofi-Aventis
-
-
-
-
-
Berlin, Duitsland
- Sanofi-Aventis
-
-
-
-
-
Helsinki, Finland
- Sanofi-Aventis
-
-
-
-
-
Dublin, Ierland
- Sanofi-Aventis
-
-
-
-
-
Mumbai, Indië
- Sanofi-Aventis
-
-
-
-
-
Istanbul, Kalkoen
- Sanofi-Aventis
-
-
-
-
-
Seoul, Korea, republiek van
- Sanofi-Aventis
-
-
-
-
-
Gouda, Nederland
- Sanofi-Aventis
-
-
-
-
-
Porto Salvo, Portugal
- Sanofi-Aventis
-
-
-
-
-
Bucharest, Roemenië
- Sanofi-Aventis
-
-
-
-
-
Moscow, Russische Federatie
- Sanofi-Aventis
-
-
-
-
-
Belgrade, Servië
- Sanofi-Aventis
-
-
-
-
-
Barcelona, Spanje
- Sanofi-Aventis
-
-
-
-
-
Taipe, Taiwan
- Sanofi-Aventis
-
-
-
-
-
Guildford, Verenigd Koninkrijk
- Sanofi-Aventis
-
-
-
-
-
Stockholm, Zweden
- Sanofi-Aventis
-
-
-
-
-
Meyrin, Zwitserland
- Sanofi-Aventis
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Inclusion Criteria:
- Type 2 diabetes for at least 1 year
- Insulin naïve
- Treated with stable doses of oral antidiabetics for at least 3 months prior to study start, including at least metformin (at least 1g/day)
- 7% ≤ HbA1c ≤ 10.5 %
- Body mass index (BMI) < 40 kg/m²
- Ability and willingness to perform blood glucose monitoring using a blood glucose meter and to use a patient diary
Exclusion Criteria:
- Type 1 diabetes
- Current or previous use of insulin (except for previous treatment of gestational diabetes or brief treatment with insulin for less than 1 week)
- Treatment with glucagon-like peptide (GLP)-1 receptor agonists or with dipeptidyl peptidase (DPP)-IV inhibitors
- Active proliferative diabetic retinopathy, as defined by the application of photocoagulation or surgery, in the 6 months before study entry or any other unstable (rapidly progressing) retinopathy that may require photocoagulation or surgery during the study (an optic fundus examination should have been performed in the 2 years prior to study entry)
- Pregnancy (women of childbearing potential must have a negative pregnancy test at study entry and a medically approved contraceptive method)
- Breast-feeding
- History of hypersensitivity to the study drugs or to drugs with a similar chemical structure
- Treatment with systemic corticosteroids in the 3 months prior to study entry
- Treatment with any investigational product in the 2 months prior to study entry
- Likelihood of requiring treatment during the study period with drugs not permitted by the clinical study protocol
- Clinically relevant cardiovascular, hepatic, neurological, endocrine, or other major disease making implementation of the protocol or interpretation of the study results difficult
- Impaired hepatic function as shown by Alamine aminotransferase (ALT) and/or Aspartate aminotransferase (AST) greater than three times the upper limit of normal range at study entry
- Impaired renal function as shown by serum creatinine ≥ 1.5 mg/dL (≥ 133 μmol/L) in men and ≥ 1.4 mg/dL (124 μmol/L) in women at study entry
- History of drug or alcohol abuse in the last year
The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Behandeling
- Toewijzing: Gerandomiseerd
- Interventioneel model: Parallelle opdracht
- Masker: Geen (open label)
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
---|---|
Experimenteel: 1
Insulin Glargine
|
Subcutaneous injection, once a day in the evening
|
Actieve vergelijker: 2
Insulin Detemir
|
Subcutaneous injection, twice a day at breakfast and before dinner
|
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Tijdsspanne |
---|---|
HbA1c recorded
Tijdsspanne: At baseline, week 12 and week 24
|
At baseline, week 12 and week 24
|
Self-monitored fasting BG in both treatment arms and pre-dinner BG in detemir arm
Tijdsspanne: On the 4 consecutive days before each visit
|
On the 4 consecutive days before each visit
|
Self-monitored BG values from 8-point 24-hour profile recorded on 2 consecutive days
Tijdsspanne: Within the week prior to baseline, week 12 and week 24
|
Within the week prior to baseline, week 12 and week 24
|
Episodes of hypoglycemia (symptomatic, total and categorized as day-time/nocturnal, severe or asymptomatic)
Tijdsspanne: All across the study
|
All across the study
|
Self-monitored BG values whenever patient experiences symptoms possibly related to hypoglycemia.
Tijdsspanne: All across the study
|
All across the study
|
Secundaire uitkomstmaten
Uitkomstmaat |
Tijdsspanne |
---|---|
Doses of insulin glargine or insulin detemir
Tijdsspanne: Daily
|
Daily
|
Laboratory fasting plasma glucose
Tijdsspanne: At baseline, week 12 and week 24
|
At baseline, week 12 and week 24
|
Insulinemia and fasting C-peptide level
Tijdsspanne: At baseline
|
At baseline
|
Lipid profile
Tijdsspanne: at baseline and week 24
|
at baseline and week 24
|
Patient reported outcomes (quality of life and treatment satisfaction)
Tijdsspanne: at baseline, week 4, week 12 and at the last visit
|
at baseline, week 4, week 12 and at the last visit
|
Safety data: occurrence of adverse events and weight
Tijdsspanne: assessed at each visit
|
assessed at each visit
|
Waist and hip circumferences
Tijdsspanne: measured at baseline, week 12 and week 24
|
measured at baseline, week 12 and week 24
|
Systolic and diastolic blood pressure
Tijdsspanne: measured at study entry, baseline, week 12 and week 24
|
measured at study entry, baseline, week 12 and week 24
|
Physical examination
Tijdsspanne: performed at study entry and at last visit.
|
performed at study entry and at last visit.
|
Medewerkers en onderzoekers
Sponsor
Onderzoekers
- Studie directeur: Valérie Pilorget, Sanofi
Publicaties en nuttige links
Studie record data
Bestudeer belangrijke data
Studie start
Primaire voltooiing (Werkelijk)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Schatting)
Updates van studierecords
Laatste update geplaatst (Schatting)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Aanvullende relevante MeSH-voorwaarden
Andere studie-ID-nummers
- LANTU_C_00579
- EUDRACT # : 2006-000324-13
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .
Klinische onderzoeken op Diabetes mellitus, type 2
-
Diabetes Foundation, IndiaNational Diabetes Obesity and Cholesterol FoundationWervingDiabetes mellitus type 2 met complicatiesIndië
-
SanofiVoltooidDiabetes mellitus type 1 - Diabetes mellitus type 2Hongarije, Russische Federatie, Duitsland, Polen, Japan, Verenigde Staten, Finland
-
India Diabetes Research Foundation & Dr. A. Ramachandran...Voltooid
-
AstraZenecaWerving
-
Daewoong Pharmaceutical Co. LTD.Nog niet aan het wervenT2DM (diabetes mellitus type 2)
-
Zhongda HospitalWervingDiabetes mellitus type 2 (T2DM)China
-
Newsoara Biopharma Co., Ltd.WervingT2DM (diabetes mellitus type 2)China
-
Shanghai Golden Leaf MedTec Co. LtdActief, niet wervendDiabetes mellitus type 2 (T2DM)China
-
SanofiVoltooid
-
Haisco Pharmaceutical Group Co., Ltd.VoltooidT2DM (diabetes mellitus type 2)China
Klinische onderzoeken op Insulin glargine
-
Universiti Sains MalaysiaVoltooid
-
Julphar Gulf Pharmaceutical IndustriesParexel; Profil Institut für Stoffwechselforschung GmbHVoltooid